Company Overview and News

20
Graphite Miners News For The Month Of September 2018

2018-09-26 seekingalpha - 2
Graphite company news - Several large successful capital raises for graphite companies. Triton Minerals lands Shandong Tianye as a cornerstone investor.
GRXXF URA SRHYY BKR BSSMF LMRMF URLNF URRE EAF ZEYYF GPHEF RNU GPHOF GRAPHITE BSM LLG APMFD NSRC KBBRF CYLYF AMVMF WKT IMYSY FMS GRPH TON ZENYF DNI BKT MUS IMYSF DMNKF SYR 509488 LMR NGPHF TLG LEMIF WWR ZEN FSRCY SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF CZSVF

19
Graphite Miners News For The Month Of August 2018

2018-08-28 seekingalpha - 2
Graphite market news - "The graphite electrode market is expected to sustain its growth momentum in the current year (2018-19) as the demand-supply gap is expected to widen."
GRXXF URA SRHYY BKR BSSMF LMRMF URLNF URRE ZEYYF GPHEF RNU ABGPF GPHOF BSM LLG APMFD NSRC KBBRF CYLYF AMVMF WKT IMYSY FMS GRPH TON ZENYF DNI BKT MUS IMYSF DMNKF SYR GLKIF LMR NGPHF TLG ALP LEMIF GLK WWR ZEN FSRCY SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF CZSVF

24
Graphite Miners News For The Month Of July 2018

2018-07-28 seekingalpha - 4
Graphite spot prices were flat in July. AMR - "Graphite prices high – batteries and electrodes could push H2 2018 prices even higher."
GRXXF URA SRHYY BKR BSSMF LMRMF URLNF URRE ZEYYF GPHEF IAG RNU ABGPF GPHOF BSM LLG APMFD NSRC KBBRF CYLYF AMVMF WKT IMYSY FMS GRPH TON ZENYF DNI BKT MUS IMYSF DMNKF SYR GLKIF LMR NGPHF TLG ALP LEMIF GLK WWR ZEN FSRCY SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF CZSVF

 
Sovereign Metals produces ultra-high ‘5-Nines’ purity graphite from Malawi project

2018-07-19 proactiveinvestors.com.au
Sovereign Metals Ltd (ASX:SVM) has produced some of the highest purity graphite in the world, using a loss on ignition process to assess the suitability of mine gate graphite concentrates from its Malingunde project in Malawi.
SVM

11
Graphite Miners News For The Month Of June 2018

2018-06-28 seekingalpha - 1
Graphite market news - Graphite to stay dominant in lithium battery anodes. Natural flake graphite market expected to move into deficit around 2020.
GRXXF URA SRHYY BKR BSSMF LMRMF URLNF URRE ZEYYF GPHEF IAG RNU GPHOF BSM LLG APMFD NSRC KBBRF CYLYF AMVMF WKT IMYSY FMS GRPH TON ZENYF DNI BKT MUS IMYSF DMNKF SYR GLKIF LMR NGPHF TLG LEMIF GLK WWR ZEN FSRCY SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF CZSVF GNG

 
Malingunde Flake Graphite Project puts Sovereign Metals at cost advantage over peers

2018-06-12 proactiveinvestors.com.au
Sovereign Metals Ltd (ASX:SVM) managing director Julian Stephens updates Proactive Investors on the company's flagship Malingunde Flake Graphite Project in Malawi.
SVM

 
Sovereign Metals upgrades saprolite-hosted graphite resource in Malawi

2018-06-12 proactiveinvestors.com.au
Sovereign Metals Limited (ASX:SVM) has revealed an updated resource of 45.7 million tonnes at 7.2% TGC (total graphitic carbon) for its Malingunde Project in Malawi.
SVM

10
Graphite Miners News For The Month Of May 2018

2018-05-30 seekingalpha
Graphite company news - Battery Minerals raises A$20m for Montepuez. Triton Minerals signs second graphite offtake deal for Ancuabe.
GRXXF URA SRHYY BKR BSSMF LMRMF URLNF URRE ZEYYF GPHEF IAG RNU GPHOF BSM LLG APMFD NSRC KBBRF CYLYF AMVMF WKT IMYSY FMS GRPH TON ZENYF DNI BKT MUS IMYSF DMNKF SYR GLKIF LMR NGPHF TLG LEMIF GLK WWR ZEN FSRCY SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF CZSVF

21
Graphite Miners News For The Month Of April 2018

2018-04-29 seekingalpha - 2
Graphite company news - Syrah Resources officially opens their Balama Graphite operation in Mozambique. Triton Minerals signs first binding offtake deal with China’s Qingdao Tianshengda Graphite.
GRXXF URA SRHYY CNA IMYSY FMS MALRY TON LMRMF MIN URLNF ZENYF URRE DNI MUS IMYSF DMNKF SYR ZEYYF GLKIF IAG LMR RNU ABGPF NGPHF TLG LLG ALP LEMIF NSRC GLK KBBRF WWR ZEN CYLYF AMVMF SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF MALRF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:SVM / SOVEREIGN METALS LIMITED on message board site Silicon Investor.

SVMI - SaVi Media Group, Inc. SVMI - SaVi Media Group, Inc. SVMI - SaVi Media Group, Inc. ServiceMaster Corp. - SVM ServiceMaster Corp. - SVM ServiceMaster Corp. - SVM